Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on adolescent vaping

LIVE: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment

Open Access 09-01-2025 | Breast Cancer | Research

Comparison of survival between unilateral and bilateral breast cancers using propensity score matching: a retrospective single-center analysis

Authors: Talar Ozler, Rusen Cosar, Necdet Sut, Dilek Nurlu, Şule Parlar, Sinan Ateş, Mert Hacı Dertli, Yusuf Kavuzlu, Sekip Kavukcu, Mert Chousein, Gokay Yıldız, Nermin Tunçbilek, Muhammet Bekir Hacıoglu, Ebru Tastekin, Sernaz Topaloğlu

Published in: Breast Cancer Research and Treatment

Login to get access

Abstract

Purpose

The characteristics of patients with bilateral and unilateral breast cancer at the time of diagnosis or during follow-up have been compared, focusing on the differences in disease-free survival and overall survival between these groups.

Methods

A total of 1,947 patients diagnosed with invasive carcinoma were included in the study. 1876 ​​(96.4%) of our patients had unilateral and 71 (3.6%) had bilateral breast cancer. Among the bilateral breast cancer patients n = 47 were metachronous, while n = 24 were synchronous.

Results

SBBC, which had the lowest OS duration, showed a statistically significant difference compared to MBCC, similar to that observed in unilateral breast cancer (p = 0.027).

Conclusion

The fact that SBBC has the lowest survival rate despite more aggressive treatments should be considered a poor prognostic factor for survival on its own.
Literature
1.
2.
Mruthyunjayappa S, Zhang K, Zhang L, Eltoum IA, Siegal GP, Wei S (2019) Synchronous and metachronous bilateral breast cancer: clinicopathologic characteristics and prognostic outcomes. Hum Pathol 92:1–9CrossRefPubMed
3.
Jia H, Zheng Y, Wang P, Wei Z, Li X, Fu G et al (2022) A retrospective study on the clinicopathologic characteristics and outcomes of 179 cases of synchronous and metachronous bilateral breast cancer in China. Clin Breast Cancer 22(3):e341–e349CrossRefPubMed
4.
5.
Hartman M, Czene K, Reilly M, Adolfsson J, Bergh J, Adami HO et al (2007) Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol 25(27):4210–4216CrossRefPubMed
6.
Shi YX, Xia Q, Peng RJ, Yuan ZY, Wang SS, An X et al (2012) Comparison of clinicopathological characteristics and prognoses between bilateral and unilateral breast cancer. J Cancer Res Clin Oncol 138(4):705–714CrossRefPubMed
7.
8.
Jobsen JJ, van der Palen J, Ong F, Riemersma S, Struikmans H (2015) Bilateral breast cancer, synchronous and metachronous; differences and outcome. Breast Cancer Res Treat 153(2):277–283CrossRefPubMed
9.
Verkooijen HM, Chatelain V, Fioretta G, Vlastos G, Rapiti E, Sappino AP et al (2007) Survival after bilateral breast cancer: results from a population-based study. Breast Cancer Res Treat 105(3):347–357CrossRefPubMed
10.
Ozturk A, Alco G, Sarsenov D, Ilgun S, Ordu C, Koksal U et al (2018) Synchronous and metachronous bilateral breast cancer: A long-term experience. J BUON 23(6):1591–1600PubMed
11.
Beinart G, Gonzalez-Angulo AM, Broglio K, Mejia J, Ruggeri A, Mininberg E et al (2007) Clinical course of 771 patients with bilateral breast cancer: characteristics associated with overall and recurrence-free survival. Clin Breast Cancer 7(11):867–874CrossRefPubMed
12.
Kollias J, Ellis IO, Elston CW, Blamey RW (2001) Prognostic significance of synchronous and metachronous bilateral breast cancer. World J Surg 25(9):1117–1124CrossRefPubMed
13.
World Medical A (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310(20):2191–2194CrossRef
14.
15.
Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 46(3):399–424CrossRefPubMedPubMedCentral
16.
17.
18.
Bradburn MJ, Clark TG, Love SB, Altman DG (2003) Survival analysis part II: multivariate data analysis–an introduction to concepts and methods. Br J Cancer 89(3):431–436CrossRefPubMedPubMedCentral
19.
20.
Haffty BG, Harrold E, Khan AJ et al (2002) Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 359:1471–1477CrossRefPubMed
21.
22.
Kuo WH, Yen AM, Lee PH, Hou MF, Chen SC, Chen KM et al (2006) Incidence and risk factors associated with bilateral breast cancer in area with early age diagnosis but low incidence of primary breast cancer: analysis of 10-year longitudinal cohort in Taiwan. Breast Cancer Res Treat 99(2):221–228CrossRefPubMed
23.
Beckmann KR, Buckingham J, Craft P, Dahlstrom JE, Zhang Y, Roder D et al (2011) Clinical characteristics and outcomes of bilateral breast cancer in an Australian cohort. Breast 20(2):158–164CrossRefPubMed
24.
Jobsen JJ, van der Palen J, Ong F, Meerwaldt JH (2003) Synchronous, bilateral breast cancer: prognostic value and incidence. Breast 12(2):83–88CrossRefPubMed
25.
Carmichael AR, Bendall S, Lockerbie L, Prescott R, Bates T (2002) The long-term outcome of synchronous bilateral breast cancer is worse than metachronous or unilateral tumours. Eur J Surg Oncol 28(4):388–391CrossRefPubMed
26.
Wang T, Liu H, Chen KX, Xun P, Li HX, Tang SC (2011) The risk factors and prognosis of bilateral primary breast cancer: a comparative study with unilateral breast cancer. Oncol Res 19(3–4):171–178CrossRefPubMed
27.
Heron DE, Komarnicky LT, Hyslop T, Schwartz GF, Mansfield CM (2000) Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease. Cancer 88(12):2739–2750CrossRefPubMed
28.
Holmberg L, Adami HO, Ekbom A, Bergstrom R, Sandstrom A, Lindgren A (1988) Prognosis in bilateral breast cancer. Effects of time interval between first and second primary tumours. Br J Cancer 58(2):191–194CrossRefPubMedPubMedCentral
29.
30.
Lee E-H, Park SK, Park B, Kim S-W, Lee MH, Ahn SH, Son BH, Yoo K-Y, Kang D, Group KR (2010) Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival a systematic review and meta-analysis. Breast Cancer Res Treat 122:11–25CrossRefPubMed
31.
Zhong Q, Peng H-L, Zhao X, Zhang L, Hwang W-T (2015) Effects of BRCA1-and BRCA2-related mutations on ovarian and breast cancer survival. a meta-analysis. Clin Cancer Res 21:211–220CrossRefPubMed
32.
Liu J, Ho PJ, Tan THL, Yeoh YS, Chew YJ, Mohamed Riza NK, Khng AJ, Goh SA, Wang Y, Oh HB, et al. (2022) Chin CH, Kwek SC, Zhang ZP, Ong DLS, Quek ST, Tan CC, Wee HL, Li J, Iau PTC, Hartman M. BREAst screening Tailored for HEr (BREATHE)-A study protocol on personalised risk-based breast cancer screening programme. PLoS One. 17(3): e0265965. https://​doi.​org/​10.​1371/​journal.​pone.​0265965.
Metadata
Title
Comparison of survival between unilateral and bilateral breast cancers using propensity score matching: a retrospective single-center analysis
Authors
Talar Ozler
Rusen Cosar
Necdet Sut
Dilek Nurlu
Şule Parlar
Sinan Ateş
Mert Hacı Dertli
Yusuf Kavuzlu
Sekip Kavukcu
Mert Chousein
Gokay Yıldız
Nermin Tunçbilek
Muhammet Bekir Hacıoglu
Ebru Tastekin
Sernaz Topaloğlu
Publication date
09-01-2025
Publisher
Springer US
Published in
Breast Cancer Research and Treatment
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-024-07606-1

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more

Transplantation can be omitted for certain MCL patients

Add-on blinatumomab improves DFS in children with ALL

Promising response to loncastuximab tesirine in lymphoma

» View more highlights on the ASH 2024 hub page

SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now
Image Credits